162010-78-8

Basic information

• Product Name: Benzoic acid, 4-(chlorosulfonyl)-3-nitro-, methyl ester
• CAS NO: 162010-78-8
• Molecular Formula: C8H6ClNO6S
• Molecular Weight: 279.658
• Mol File: 162010-78-8.mol

Chemical Properties

• CAS DataBase Reference: Benzoic acid, 4-(chlorosulfonyl)-3-nitro-, methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 4-(chlorosulfonyl)-3-nitro-, methyl ester(162010-78-8)
• EPA Substance Registry System: Benzoic acid, 4-(chlorosulfonyl)-3-nitro-, methyl ester(162010-78-8)

Safety Data

• Hazardous Substances Data: 162010-78-8(Hazardous Substances Data)

Upstream product

• 14719-83-6 methyl 3-nitro-4-chlorobenzoate 
• 59515-34-3 4-mercapto-3-nitro-benzoic acid methyl ester 
• 329-59-9 4-fluoro-3-nitro-benzoic acid methyl ester 

Downstream Products

• 263758-25-4 C₂₂H₂₅⁽²⁾H₂N₃O₈S 
• 330798-29-3 methyl 4-[({2-[(tert-butoxycarbonyl)(methyl)amino]ethyl}amino)sulphonyl]-3-nitrobenzoate 
• 330798-30-6 methyl 4-[({2-[(tert-butoxycarbonyl)(d³-methyl)amino]ethyl}amino)sulphonyl]-3-nitrobenzoate 
• 321352-71-0 4-{3-(3-tert-butoxycarbonylamino-prop-1-ynyl)-4-methoxy-5-[3-(2,2,2-trifluoro-acetylamino)-prop-1-ynyl]-phenylsulfamoyl}-3-nitro-benzoic acid methyl ester 
• 575434-16-1 methyl 4-(3-tert-butoxycarbonylaminopropylsulfamoyl)-3-nitrobenzoate 
• 330798-31-7 methyl 4-[([3-(9-anthryl)propyl]{2-[(tert-butoxycarbonyl)(methyl)amino]ethyl}amino)sulphonyl]-3-nitrobenzoate 
• 330798-32-8 methyl 4-[([3-(9-anthryl)propyl]{2-[(tert-butoxycarbonyl)(d³-methyl)amino]ethyl}amino)sulphonyl]-3-nitrobenzoate 
• 197728-18-0 4-(4-Methyl-benzylsulfamoyl)-3-nitro-benzoic acid 
• 263758-26-5 C₂₁H₂₃⁽²⁾H₂N₃O₈S 
• 263758-27-6 C₂₂H₂₇N₃O₈S 
• 162010-79-9 4-(Aminosulfonyl)-3-nitrobenzenecarboxylic acid, methyl ester 
• 199535-36-9 3-Amino-4-sulfamoyl-benzoic acid methyl ester 

Relevant articles and documents

Utility of the 2-Nitrobenzenesulfonamide Group as a Chemical Linker for Enhanced Extracellular Stability and Cytosolic Cleavage in siRNA-Conjugated Polymer Systems

Herein we report the 2-nitrobenzenesulfonamide group as a new chemical linker that responds to the difference in redox potential across the cellular membrane, toward the construction of siRNA–polymer conjugates. PEG-conjugated to siRNA via the 2-nitrobenz

CRYSTAL FORM OF TRICYCLIC COMPOUNDS AND APPLICATION THEREOF

本發明公開了式(I)所示化合物的A晶型及B晶型，及其在製備治療HBV相關疾病藥物中的應用。 The invention discloses “A”crystal form and“B”crystal form of a compound represented by formula (I) and an application thereof in a preparation of a medicament for treating HBV-related diseases.

INDOLE DERIVATIVE USED AS CRTH2 INHIBITOR

The present application discloses an indole as represented by formula (I) used as a CRTH2 inhibitor, and a pharmaceutically acceptable salt or tautomer of the indole, and an application of same in treating a disease related to a CRTH2 receptor.

As CRTH2 inhibitor of indole compounds (by machine translation)

The application discloses a formula (I) as shown in CRTH2 inhibitor of indole compound or its pharmaceutically acceptable salt, and their use in the treatment with the CRTH2 receptor-related diseases in the application. (by machine translation)

Novel Sulfonaminoquinoline Hepcidin Antagonists

The present invention relates to novel hepcidin antagonists, pharmaceutical compositions comprising them and the use thereof as medicaments for the use in the treatment of iron metabolism disorders, such as, in particular, iron deficiency diseases and anemias, in particular anemias in connection with chronic inflammatory diseases.

A novel, chemically robust, amine releasing linker

A polymer supported sulfonamide 1, based on an amine protective group, has been developed as a novel linker for solid phase organic synthesis. The linker permits the immobilisation of alcohol substrates, and releases N-protected amines under mild nucleophilic cleavage conditions.

Non-peptidic angiotensin-II-receptor-antagonists

Novel compounds having the formula STR1 wherein R 1, R 2, X and Y are as defined herein. These compounds inhibit the action of angiotensin II and are useful, therefore, for example, as antihypertensive agents.